Modified Ham Test for Atypical Hemolytic Uremic Syndrome
Overview
Authors
Affiliations
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by excessive activation of the alternative pathway of complement (APC). Atypical HUS is frequently a diagnosis of exclusion. Differentiating aHUS from other TMAs, especially thrombotic thrombocytopenic purpura (TTP), is difficult due to overlapping clinical manifestations. We sought to develop a novel assay to distinguish aHUS from other TMAs based on the hypothesis that paroxysmal nocturnal hemoglobinuria cells are more sensitive to APC-activated serum due to deficiency of glycosylphosphatidylinositol- anchored complement regulatory proteins (GPI-AP). Here, we demonstrate that phosphatidylinositol-specific phospholipase C-treated EA.hy926 cells and PIGA-mutant TF-1 cells are more susceptible to serum from aHUS patients than parental EA.hy926 and TF-1 cells. We next studied 31 samples from 25 patients with TMAs, including 9 with aHUS and 12 with TTP. Increased C5b-9 deposition was evident by confocal microscopy and flow cytometry on GPI-AP-deficient cells incubated with aHUS serum compared with heat-inactivated control, TTP, and normal serum. Differences in cell viability were observed in biochemically GPI-AP-deficient cells and were further increased in PIGA-deficient cells. Serum from patients with aHUS resulted in a significant increase of nonviable PIGA-deficient TF-1 cells compared with serum from healthy controls (P < .001) and other TMAs (P < .001). The cell viability assay showed high reproducibility, sensitivity, and specificity in detecting aHUS. In conclusion, we developed a simple, rapid, and serum-based assay that helps to differentiate aHUS from other TMAs.
Martin M, Llorens-Cebria C, Leon-Roman J, Perurena-Prieto J, Perez-Beltran V, Saumell S Kidney Int Rep. 2024; 9(7):2227-2239.
PMID: 39081726 PMC: 11284441. DOI: 10.1016/j.ekir.2024.04.022.
Venou T, Vetsiou E, Varelas C, Daniilidis A, Psarras K, Koravou E J Pers Med. 2024; 14(4).
PMID: 38673014 PMC: 11051193. DOI: 10.3390/jpm14040387.
Can complement activation be the missing link in antiphospholipid syndrome?.
Venturelli V, Maranini B, Tohidi-Esfahani I, Isenberg D, Cohen H, Efthymiou M Rheumatology (Oxford). 2024; 63(12):3243-3254.
PMID: 38483257 PMC: 11637425. DOI: 10.1093/rheumatology/keae178.
Gavriilaki E, Bousiou Z, Batsis I, Vardi A, Mallouri D, Koravou E Int J Mol Sci. 2024; 25(1).
PMID: 38203404 PMC: 10778584. DOI: 10.3390/ijms25010231.
Medical consult: aHUS, TTP? How to distinguish and what to do.
Story C, Gerber G, Chaturvedi S Hematology Am Soc Hematol Educ Program. 2023; 2023(1):745-753.
PMID: 38066937 PMC: 10727109. DOI: 10.1182/hematology.2023000501.